Fredun Pharmaceuticals Intrinsic Value
Fredun Pharmaceuticals intrinsic value. Fredun Pharmaceuticals (FREDUN) median intrinsic value is ₹926.67 from 9 valuation models (range ₹512–₹3416), vs current price ₹1708.00 — -45.7% downside (Trading Above Calculated Value), margin of safety -84.3%. Browse Fredun Pharmaceuticals financial data for revenue, profit, balance sheet and cash flow data.
FREDUN Valuation Methods Summary — DCF, Graham Number & P/E
Fredun Pharmaceuticals intrinsic value across 9 models vs current price ₹1708.00 — upside/downside and value range per method. For current market price and key ratios, visit FREDUN share price screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹967.12 | ₹773.70 - ₹1160.54 | -43.4% | EPS: ₹43.96, Sector P/E: 22x |
| Book Value Method | asset | ₹926.67 | ₹834.00 - ₹1019.34 | -45.7% | Book Value/Share: ₹463.33, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹3416.00 | ₹3074.40 - ₹3757.60 | +100.0% | Revenue/Share: ₹1773.33, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹2733.33 | ₹2460.00 - ₹3006.66 | +60.0% | EBITDA: ₹164.00Cr, EV/EBITDA: 10x |
| PEG Ratio Method | growth | ₹512.40 | ₹461.16 - ₹563.64 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹679.18 | ₹611.26 - ₹747.10 | -60.2% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹2026.67 | ₹1824.00 - ₹2229.34 | +18.7% | ROE: 27.3%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹676.97 | ₹609.27 - ₹744.67 | -60.4% | EPS: ₹43.96, BVPS: ₹463.33 |
| Dividend Yield Method | dividend | ₹512.40 | ₹461.16 - ₹563.64 | -70.0% | DPS: ₹0.70, Target Yield: 2.5% |
FREDUN Intrinsic Value vs Market Price — All Valuation Models
Fredun Pharmaceuticals fair value range ₹512–₹3416 vs current market price ₹1708.00 across 9 valuation models. Analyse Fredun Pharmaceuticals ownership pattern to track promoter, FII and institutional holdings.
FREDUN Intrinsic Value Analysis — Undervalued or Overvalued?
Fredun Pharmaceuticals median intrinsic value ₹926.67, current price ₹1708.00 — Trading Above Calculated Value by 45.7%, margin of safety -84.3%.
What is the intrinsic value of FREDUN?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Fredun Pharmaceuticals (FREDUN) is ₹926.67 (median value). With the current market price of ₹1708.00, this represents a -45.7% variance from our estimated fair value.
The valuation range spans from ₹512.40 to ₹3416.00, indicating ₹512.40 - ₹3416.00.
Is FREDUN undervalued or overvalued?
Based on our multi-method analysis, Fredun Pharmaceuticals (FREDUN) appears to be trading above calculated value by approximately 45.7%.
FREDUN Financial Health — Key Ratios vs Industry Benchmarks
Fredun Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 27.3% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 15.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.66x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
FREDUN Cash Flow Quality — Operating & Free Cash Flow
Fredun Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹12 Cr | ₹-25 Cr | Positive Operating Cash Flow | 6/10 |
| March 2025 | ₹-17 Cr | ₹-20 Cr | Negative Cash Flow | 3/10 |